TNF inhibitor explained

A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their treatment. The important side effects of TNF inhibitors include lymphomas, infections (especially reactivation of latent tuberculosis), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.[1]

The global market for TNF inhibitors in 2008 was [2] and in 2009.[3]

Examples

Inhibition of TNF effects can be achieved with a monoclonal antibody such as infliximab,[4] adalimumab, certolizumab pegol, and golimumab, or with a circulating receptor fusion protein such as etanercept.

Thalidomide and its derivatives lenalidomide and pomalidomide are also active against TNF.

While most clinically useful TNF inhibitors are monoclonal antibodies, some are simple molecules such as xanthine derivatives[5] (e.g. pentoxifylline)[6] and bupropion.[7]

Several 5-HT2A agonist hallucinogens including (R)-DOI, TCB-2, LSD and LA-SS-Az have unexpectedly also been found to act as potent inhibitors of TNF, with DOI being the most active, showing TNF inhibition in the picomolar range, an order of magnitude more potent than its action as a hallucinogen.[8] [9] [10]

Medical uses

Rheumatoid arthritis

The role of TNF as a key player in the development of rheumatoid arthritis was originally demonstrated by Kollias and colleagues in proof of principle studies in transgenic animal models.[11] [12]

TNF levels have been shown to be raised in both the synovial fluid and synovium of patients with rheumatoid arthritis. This leads to local inflammation through the signalling of synovial cells to produce metalloproteinases and collagenase.[13]

Clinical application of anti-TNF drugs in rheumatoid arthritis was demonstrated by Marc Feldmann and Ravinder N. Maini, who won the 2003 Lasker Award for their work.[14] Anti-TNF compounds help eliminate abnormal B cell activity.[15] [16]

Therapy which combines certain anti-TNF agents such as etanercept with DMARDs such as methotrexate has been shown to be more effective at restoring quality of life to sufferers of rheumatoid arthritis than using either drug alone.[13]

Skin disease

Clinical trials regarding the effectiveness of these drugs on hidradenitis suppurativa are ongoing.[17]

The National Institute of Clinical Excellence (NICE) has issued guidelines for the treatment of severe psoriasis using the anti-TNF drugs etanercept and adalimumab as well as the anti-IL12/23 biological treatment ustekinumab. In cases where more conventional systemic treatments such as psoralen combined with ultraviolet A treatment (PUVA), methotrexate, and ciclosporin have failed or can not be tolerated, these newer biological agents may be prescribed. Infliximab may be used to treat severe plaque psoriasis if aforementioned treatments fail or can not be tolerated.[18]

Gastrointestinal disease

In 2010 The National Institute of Clinical Excellence (NICE) in the UK issued guidelines for the treatment of severe Crohn's Disease with infliximab and adalimumab.[19]

Cancer

Anti-TNF therapy has shown only modest effects in cancer therapy. Treatment of renal cell carcinoma with infliximab resulted in prolonged disease stabilization in certain patients. Etanercept was tested for treating patients with breast cancer and ovarian cancer showing prolonged disease stabilization in certain patients via downregulation of IL-6 and CCL2. On the other hand, adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo.[20]

Side effects

Cancer

The U.S. Food and Drug Administration continues to receive reports of a rare cancer of white blood cells (known as hepatosplenic T-cell lymphoma or HSTCL), primarily in adolescents and young adults being treated for Crohn's disease and ulcerative colitis with TNF blockers, as well as with azathioprine, and/or mercaptopurine.[21]

Opportunistic infections

TNF inhibitors put patients at increased risk of certain opportunistic infections. The FDA has warned about the risk of infection from two bacterial pathogens, Legionella and Listeria. People taking TNF blockers are at increased risk for developing serious infections that may lead to hospitalization or death due to certain bacterial, mycobacterial, fungal, viral, and parasitic opportunistic pathogens.[22]

Tuberculosis

In patients with latent Mycobacterium tuberculosis infection, active tuberculosis (TB) may develop soon after the initiation of treatment with infliximab.[23] Before prescribing a TNF inhibitor, physicians should screen patients for latent tuberculosis. The anti-TNF monoclonal antibody biologics infliximab, golimumab, certolizumab and adalimumab, and the fusion protein etanercept, which are all currently approved by the FDA for human use, have warnings which state that patients should be evaluated for latent TB infection, and if it is detected, preventive treatment should be initiated prior to starting therapy with these medications.

Fungal infections

The FDA issued a warning on September 4, 2008, that patients on TNF inhibitors are at increased risk of opportunistic fungal infections such as pulmonary and disseminated histoplasmosis, coccidioidomycosis, and blastomycosis. They encourage clinicians to consider empiric antifungal therapy in certain circumstances to all patients at risk until the pathogen is identified.[24] A recent review showed that anti-TNFα agents associate with increased infection risks for both endemic and opportunistic invasive fungal infections, particularly when given late in the overall course of treatment of the underlying disease, and in young patients receiving concomitant cytotoxic or augmented immunosuppressive therapy.[25]

Multiple sclerosis and demyelinating disorders

In 1999 a randomized control trial was conducted testing a TNF-alpha inhibitor prototype, Lenercept, for the treatment of multiple sclerosis (MS). However, the patients in the study who received the drug had significantly more exacerbations and earlier exacerbations of their disease than those who did not.[26]

Case reports have also come out suggesting the possibility that anti-TNF-alpha agents not only may worsen, but may cause new-onset Multiple Sclerosis or other demyelinating disorders in some patients.[27] A 2018 case report described an Italian man with plaque psoriasis who developed MS after starting entanercept. Their literature review at that time identified 34 other cases of demyelinating disease developing after the initiation of an anti-TNF drug.[28] Thus, anti-TNF-alpha drugs are contraindicated in patients with MS, and the American Academy of Dermatology recommends avoiding their use in those with a first degree relative with MS.[29]

Several other monoclonal antibodies like adalimumab,[30] [31] pembrolizumab,[32] nivolumab, and infliximab[33] have been reported to trigger MS as an adverse event.[34]

The risk of anti-TNF-associated demyelination is not associated with genetic variants of multiple sclerosis. In some studies, there were clinical differences to multiple sclerosis as 70% of the patients with anti-TNF-induced demyelination. The symptoms of demyelination do not resolve with corticosteroids, intravenous immunoglobulin or plasma exchange, and is not clear whether MS therapies are effective in anti-TNF-induced demyelination.[35]

Paradoxical psoriasis

Despite their good safety profile, one of the common adverse events and side effects associated with TNF-α inhibitors is the occurrence of paradoxical psoriasis. Paradoxical psoriasis is defined as the development of psoriatic lesions or as an exacerbation of pre-existent psoriatic lesions, in patients with or without a prior history of psoriasis, while undergoing treatment with TNF-α inhibitors, such as infliximab, adalimumab, and etanercept for their underlying inflammatory disease.[36] [37] [38] The first case of paradoxical psoriasis induced by TNF-α inhibitors was reported in a patient suffering from inflammatory bowel disease. Subsequently, an increasing number of cases were reported in IBD cohorts and in patients suffering from other chronic immune-mediated inflammatory diseases such as rheumatoid arthritis. This increase was positively correlated with the increasing use of TNF-α inhibitors. The rates of paradoxical psoriasis reported across observational studies range from 2% to 5%, with higher rates observed in female patients. The time to onset from induction therapy to development of psoriatic lesions can range from anywhere from a few days to a few months. The most common clinical presentations are pustular psoriasis, plaque psoriasis and guttate psoriasis, with nail and scalp involvement. Moreover, some patients may experience more than one type of psoriatic lesion and/or have lesions across multiple locations.

Anti-TNF agents in nature

TNF or its effects are inhibited by several natural compounds, including curcumin[39] [40] [41] [42] (a compound present in turmeric), and catechins (in green tea). Cannabidiol[43] and Echinacea purpurea also seem to have anti-inflammatory properties through inhibition of TNF-α production, although this effect may be mediated through cannabinoid CB1 or CB2 receptor-independent effects.[44]

5-HT2A receptor agonists have also been shown to have potent inhibitory effects on TNF-α, including psilocybin found in many species of mushrooms.[45] [46]

Thymoquinone, a compound found in the flower Nigella sativa, has been studied for possible TNF-α inhibition and related benefits for autoimmune disorder treatment.[47] [48] [49] [50]

History

Early experiments associated TNF with the pathogenesis of bacterial sepsis. Thus, the first preclinical studies using polyclonal antibodies against TNF-alpha were performed in animal models of sepsis in 1985 and showed that anti-TNF antibodies protected mice from sepsis.[51] [52] However, subsequent clinical trials in patients with sepsis showed no significant benefit. It wasn't until 1991 that studies in a transgenic mouse model of overexpressed human TNF provided the pre-clinical rationale for a causal role of TNF in the development of polyarthritis and that anti-TNF treatments could be effective against human arthritides.[11] This was later confirmed in clinical trials[53] and led to the development of the first biological therapies for rheumatoid arthritis.

Notes and References

  1. Scheinfeld N . A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab . The Journal of Dermatological Treatment . 15 . 5 . 280–294 . September 2004 . 15370396 . 10.1080/09546630410017275 . 43332215 .
  2. Pappas DA, Bathon JM, Hanicq D, Yasothan U, Kirkpatrick P . Golimumab . Nature Reviews. Drug Discovery . 8 . 9 . 695–696 . September 2009 . 19721444 . 10.1038/nrd2982 .
  3. Web site: Top Ten/Twenty Best Selling Drugs 2009 . 2011-09-08 . dead . https://web.archive.org/web/20110917104658/http://knol.google.com/k/top-ten-twenty-best-selling-drugs-2009 . 2011-09-17 .
  4. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C . Binding and functional comparisons of two types of tumor necrosis factor antagonists . The Journal of Pharmacology and Experimental Therapeutics . 301 . 2 . 418–426 . May 2002 . 11961039 . 10.1124/jpet.301.2.418 . 43021140 .
  5. Essayan DM . Cyclic nucleotide phosphodiesterases . The Journal of Allergy and Clinical Immunology . 108 . 5 . 671–680 . November 2001 . 11692087 . 10.1067/mai.2001.119555 . 21528985 . free .
  6. Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U . Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages . American Journal of Respiratory and Critical Care Medicine . 159 . 2 . 508–511 . February 1999 . 9927365 . 10.1164/ajrccm.159.2.9804085 .
  7. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB . A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice . International Immunopharmacology . 6 . 6 . 903–907 . June 2006 . 16644475 . 10.1016/j.intimp.2005.12.007 .
  8. Miller KJ, Gonzalez HA . Serotonin 5-HT2A receptor activation inhibits cytokine-stimulated inducible nitric oxide synthase in C6 glioma cells . Annals of the New York Academy of Sciences . 861 . 1 . 169–173 . December 1998 . 9928254 . 10.1111/j.1749-6632.1998.tb10188.x . 23264746 . 1998NYASA.861..169M .
  9. Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD . Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency . The Journal of Pharmacology and Experimental Therapeutics . 327 . 2 . 316–323 . November 2008 . 18708586 . 10.1124/jpet.108.143461 . 25374241 .
  10. Pelletier M, Siegel RM . Wishing away inflammation? New links between serotonin and TNF signaling . Molecular Interventions . 9 . 6 . 299–301 . December 2009 . 20048135 . 2861806 . 10.1124/mi.9.6.5 .
  11. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G . Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis . The EMBO Journal . 10 . 13 . 4025–4031 . December 1991 . 1721867 . 453150 . 10.1002/j.1460-2075.1991.tb04978.x .
  12. Brenner D, Blaser H, Mak TW . Regulation of tumour necrosis factor signalling: live or let die . Nature Reviews. Immunology . 15 . 6 . 362–374 . June 2015 . 26008591 . 10.1038/nri3834 . 1550839 .
  13. Ma X, Xu S . TNF inhibitor therapy for rheumatoid arthritis . Biomedical Reports . 1 . 2 . 177–184 . March 2013 . 24648915 . 3956207 . 10.3892/br.2012.42 .
  14. Feldmann M, Maini RN . Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases . Nature Medicine . 9 . 10 . 1245–1250 . October 2003 . 14520364 . 10.1038/nm939 . 52860838 .
  15. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, Miller CH, Dutcher PO, Hadley JA, Sanz I . 6 . Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks . Journal of Immunology . 180 . 2 . 688–692 . January 2008 . 18178805 . 10.4049/jimmunol.180.2.688 . 45744340 . free .
  16. Web site: A new view of drugs used to treat rheumatoid arthritis from medicineworld.org. medicineworld.org. 16 April 2018.
  17. Haslund P, Lee RA, Jemec GB . Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors . Acta Dermato-Venereologica . 89 . 6 . 595–600 . November 2009 . 19997689 . 10.2340/00015555-0747 . free .
  18. Web site: Psoriasis Association. psoriasis-association.org.uk. 16 April 2018.
  19. Web site: Infliximab and adalimumab for the treatment of Crohn's disease 1-guidance Guidance and guidelines NICE. www.nice.org.uk. 19 May 2010 . 2016-12-04.
  20. Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA . TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis . Cytokine . 89 . 127–135 . January 2017 . 26854213 . 10.1016/j.cyto.2016.01.021 .
  21. Web site: FDA Alert: Tumor Necrosis Factor (TNF) blockers, Azathioprine and/or Mercaptopurine: Update on Reports of Hepatosplenic T-Cell Lymphoma in Adolescents and Young Adults. drugs.com. 16 April 2018.
  22. Web site: FDA Alert: Tumor Necrosis Factor-alpha (TNFα) Blockers: Label Change - Boxed Warning Updated for Risk of Infection from Legionella and Listeria. drugs.com. 16 April 2018.
  23. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM . 6 . Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent . The New England Journal of Medicine . 345 . 15 . 1098–1104 . October 2001 . 11596589 . 10.1056/NEJMoa011110 . free .
  24. FDA: Manufacturers of TNF-Blocker Drugs Must Highlight Risk of Fungal Infections . U.S. Food and Drug Administration (FDA) . September 4, 2008 . 2009-11-15.
  25. Tragiannidis A, Kyriakidis I, Zündorf I, Groll AH . Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors . Mycoses . 60 . 4 . 222–229 . April 2017 . 27766695 . 10.1111/myc.12576 . 23722641 .
  26. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group . Neurology . 53 . 3 . 457–465 . August 1999 . 10449104 . 10.1212/WNL.53.3.457 . 26126291 . free .
  27. Kemanetzoglou E, Andreadou E . CNS Demyelination with TNF-α Blockers . Current Neurology and Neuroscience Reports . 17 . 4 . 36 . April 2017 . 28337644 . 5364240 . 10.1007/s11910-017-0742-1 .
  28. Napolitano M, Balato N, Ayala F, Cirillo T, Balato A . Multiple sclerosis following anti-tumor necrosis factor-alpha therapy for psoriasis: first case in Italy? . Giornale Italiano di Dermatologia e Venereologia . 153 . 4 . 567–572 . August 2018 . 25692775 . 10.23736/S0392-0488.17.04992-6 .
  29. Mansouri B, Horner ME, Menter A . Tumor Necrosis Factor-α Inhibitor Use in Psoriasis Patients With a First-degree Relative With Multiple Sclerosis . Journal of Drugs in Dermatology . 14 . 8 . 876–878 . August 2015 . 26267733 .
  30. Engel S, Luessi F, Mueller A, Schopf RE, Zipp F, Bittner S . PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders . Therapeutic Advances in Neurological Disorders . 13 . 1756286419895155 . 2 January 2020 . 31921355 . 6940603 . 10.1177/1756286419895155 .
  31. Alnasser Alsukhni R, Jriekh Z, Aboras Y . Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature . Case Reports in Medicine . 2016 . 1423131 . 2016-10-20 . 27840642 . 5093248 . 10.1155/2016/1423131 . free .
  32. Romeo MA, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V, Filippi M . Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer . Journal of Neurology . 266 . 12 . 3163–3166 . December 2019 . 31586260 . 10.1007/s00415-019-09562-z . 203654410 .
  33. Kalinowska-Lyszczarz A, Fereidan-Esfahani M, Guo Y, Lucchinetti CF, Tobin WO . Pathological findings in central nervous system demyelination associated with infliximab . Multiple Sclerosis . 26 . 9 . 1124–1129 . August 2020 . 31845616 . 7297659 . 10.1177/1352458519894710 .
  34. Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL . Multiple sclerosis outcomes after cancer immunotherapy . Clinical & Translational Oncology . 21 . 10 . 1336–1342 . October 2019 . 30788836 . 6702101 . 10.1007/s12094-019-02060-8 .
  35. Williams I, Uhlig HH . Demyelination After Anti-TNF Therapy: Who is at Risk? . Journal of Crohn's & Colitis . 14 . 12 . 1651–1652 . December 2020 . 33026456 . 10.1093/ecco-jcc/jjaa144 . free .
  36. Bucalo . Agostino . Rega . Federica . Zangrilli . Arianna . Silvestri . Valentina . Valentini . Virginia . Scafetta . Giorgia . Marraffa . Federica . Grassi . Sara . Rogante . Elena . Piccolo . Arianna . Cucchiara . Salvatore . Viola . Franca . Bianchi . Luca . Ottini . Laura . Richetta . Antonio . January 2020 . Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers . International Journal of Molecular Sciences . en . 21 . 21 . 7873 . 10.3390/ijms21217873 . 33114187 . 7660646 . 1422-0067 . free .
  37. Vasconcellos . Jaqueline Barbeito de . Pereira . Daniele do Nascimento . Vargas . Thiago Jeunon de Sousa . Levy . Roger Abramino . Pinheiro . Geraldo da Rocha Castelar . Cursi . Ígor Brum . September–October 2016 . Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis . Anais Brasileiros de Dermatologia . en . 91 . 5 suppl 1 . 137–139 . 10.1590/abd1806-4841.20164456 . 28300922 . 5325021 . 0365-0596.
  38. Toussirot . Éric . Aubin . François . 2016-07-01 . Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview . RMD Open . en . 2 . 2 . e000239 . 10.1136/rmdopen-2015-000239 . 2056-5933 . 27493788. 4964220 .
  39. Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, Simms HH, Wang P . 6 . The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma . Critical Care Medicine . 34 . 7 . 1874–1882 . July 2006 . 16715036 . 10.1097/01.CCM.0000221921.71300.BF . 71135736 .
  40. Okunieff P, Xu J, Hu D, Liu W, Zhang L, Morrow G, Pentland A, Ryan JL, Ding I . 6 . Curcumin protects against radiation-induced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines . International Journal of Radiation Oncology, Biology, Physics . 65 . 3 . 890–898 . July 2006 . 16751071 . 10.1016/j.ijrobp.2006.03.025 .
  41. Gulcubuk A, Altunatmaz K, Sonmez K, Haktanir-Yatkin D, Uzun H, Gurel A, Aydin S . Effects of curcumin on tumour necrosis factor-alpha and interleukin-6 in the late phase of experimental acute pancreatitis . Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine . 53 . 1 . 49–54 . February 2006 . 16411910 . 10.1111/j.1439-0442.2006.00786.x .
  42. Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN . The effect of turmeric extracts on inflammatory mediator production . Phytomedicine . 12 . 6–7 . 445–452 . June 2005 . 16008121 . 10.1016/j.phymed.2003.12.011 .
  43. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO . Cannabidiol--recent advances . Chemistry & Biodiversity . 4 . 8 . 1678–1692 . August 2007 . 17712814 . 10.1002/cbdv.200790147 . 3689072 .
  44. Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, Altmann KH, Gertsch J . 6 . Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects . The Journal of Biological Chemistry . 281 . 20 . 14192–14206 . May 2006 . 16547349 . 10.1074/jbc.M601074200 . 1570400 . free .
  45. Nkadimeng SM, Steinmann CM, Eloff JN . Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells . Journal of Inflammation Research . 14 . 3729–3738 . 2021 . 34385833 . 8352634 . 10.2147/JIR.S317182 . free .
  46. Nau F, Yu B, Martin D, Nichols CD . Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo . PLOS ONE . 8 . 10 . e75426 . 2013-10-02 . 24098382 . 3788795 . 10.1371/journal.pone.0075426 . free . 2013PLoSO...875426N .
  47. Umar S, Hedaya O, Singh AK, Ahmed S . Thymoquinone inhibits TNF-α-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation . Toxicology and Applied Pharmacology . 287 . 3 . 299–305 . September 2015 . 26134265 . 4549173 . 10.1016/j.taap.2015.06.017 .
  48. Farkhondeh T, Samarghandian S, Shahri AM, Samini F . The Neuroprotective Effects of Thymoquinone: A Review . Dose-Response . 16 . 2 . 1559325818761455 . 2018 . 29662431 . 5898665 . 10.1177/1559325818761455 .
  49. Ali MY, Akter Z, Mei Z, Zheng M, Tania M, Khan MA . Thymoquinone in autoimmune diseases: Therapeutic potential and molecular mechanisms . Biomedicine & Pharmacotherapy . 134 . 111157 . February 2021 . 33370631 . 10.1016/j.biopha.2020.111157 . 229714190 . free .
  50. Malik S, Singh A, Negi P, Kapoor VK . Thymoquinone: A small molecule from nature with high therapeutic potential . Drug Discovery Today . 26 . 11 . 2716–2725 . November 2021 . 34303824 . 10.1016/j.drudis.2021.07.013 . 236431672 .
  51. Vilcek J . First demonstration of the role of TNF in the pathogenesis of disease . Journal of Immunology . 181 . 1 . 5–6 . July 2008 . 18566362 . 10.4049/jimmunol.181.1.5 . 44529219 . free .
  52. Beutler B, Milsark IW, Cerami AC . Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 1985, 229(4716):869-871. Classical article . Journal of Immunology . 181 . 1 . 7–9 . July 2008 . 10.1126/science.3895437 . 18566363 .
  53. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H . 6 . Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis . Lancet . 344 . 8930 . 1105–1110 . October 1994 . 7934491 . 10.1016/S0140-6736(94)90628-9 . 22776233 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "TNF inhibitor".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.